By CDMOWorld Staff | October 28, 2025
TAMPA, Fla. — Global CDMO leader Catalent, Inc. has unveiled a new corporate identity anchored by the message “Championing the Missions that Matter™,” marking a strategic evolution in how the company positions itself within the pharmaceutical, biotech, and consumer health sectors.
The rebrand, announced today at CPHI Frankfurt and SupplySide Global, emphasizes Catalent’s deepened commitment to exceptional customer service and its “Patient First” philosophy. The initiative is designed to highlight the company’s role not just as a manufacturing partner, but as a collaborative force advancing its customers’ most critical missions — from early development to global delivery.
“Every medicine, therapy, and product we help develop exemplifies our commitment to put patients first,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “This new brand and simplified approach speak not only to who we are today, but to the impact we have on global health.”
The rebranding comes as Catalent continues to build momentum following its transition to private ownership under Novo Holdings in December 2024. The company recently announced its new global headquarters in Tampa, Florida, solidifying its operational base while maintaining more than 40 sites worldwide.
“Our new branding reflects exactly who we are and how we deliver — a company that puts patients first, provides tailored solutions with unparalleled service, and champions every customer’s mission as if it were our own,” said Trish Hunt, Group Vice President and Chief Marketing Officer.
Over the past decade, Catalent has supported products representing half of all FDA approvals, produces over 60 billion doses annually, and manages more than 1,000 active development programs at any given time. This scale allows Catalent to serve organizations of every size — from virtual biotechs to global pharmaceutical companies — with end-to-end development and manufacturing capabilities.
The new corporate brand will roll out across Catalent’s global operations, website, and marketing channels in the coming months, with the company emphasizing uninterrupted service to its clients during the transition.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives. Through its Patient First approach, Catalent delivers end-to-end solutions for pharmaceutical, biotech, and consumer health partners, from development and manufacturing to global supply. With more than 40 facilities worldwide and thousands of scientists and technicians, Catalent supports over 1,000 active development programs and produces over 60 billion doses annually. Learn more at www.catalent.com.
